



SUPPORTING INNOVATION AND TECHNOLOGY TRANSFER IN ONCOLOGY

RIBOVAX Telomium



CONTEXT & BACKGROUND

Telomium is a biotechnology company developing a therapeutic product for cancer immunotherapy. Our first-in-class ribonucleoprotein vaccine has the ability to mimic a viral attack and induce an auto-immune reaction targeted against any form of cancer, without causing significant side effects. This self-vectored and self-adjuvanted vaccine is prepared from a patented, safe, competitive and scalable yeast-based technology using a breakthrough innovation in the production of recombinant telomerase



INNOVATIVE COMPONENT & TECHNOLOGY

A telomerase ribonucleoprotein particle (conjugated protein-RNA vaccine)



OBJECTIVES

To induce tumor specific T-cell responses that can fight cancer



DEVELOPMENT & MATURATION STAGE

Ongoing POC



TARGET POPULATION

All cancers. First indication (HCC,SCLC, GBM)



TARGET PROFILE

Anyone with a normal immune function as telomerase is reactivated in 90% of cancers

SCOPE

A second chance for telomerase reverse transcriptase in anticancer immunotherapy

KEYWORDS

Telomerase immunotherapy



INTELLECTUAL PROPERTY & PATIENT CO-OWNER(S)

License obtained from a patent owned by the University Paris 5



STRENGTHS & COMPETITIVE ADVANTAGES

Best in class (for telomerase as the target) & First in class (for  vaccine technology)



INDUSTRIAL APPLICATIONS & OPPORTUNITIES

Combination with immunomodulators

